Two subjects experienced SAEs, one administered TransCon PTH 12 μg PTH(1‐34) developed catheter‐site phlebitis leading to hospitalization and one administered placebo developed bacteremia; neither SAE was assessed to be related to study drug and both resolved without sequelae. The gene discussed is PTH; the disease is phlebitis.